ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

Branded and Biosimilar Ophthalmology

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · compiled

Tender information last checkedLast checked 30 Sept 2026, 07:16.

Opportunity overview

Supply of Branded and Biosimilar Ophthalmology to NHS Scotland.

Awarded to

Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.

Bayer Plc

Ai Match
Contract value
£9.3m
Awarded
Not supplied
Contract signed
30 Oct 2025
Award ID
076640-2025-2
Status
active
Location
Reading, UKM, RG2 6AD, United Kingdom

Celltrion Healthcare United Kingdom Limited

Match pending…
Shared contract value
£8.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 5 awarded suppliers
Award ID
076640-2025-3
Status
active
Location
Slough, UKM, SL1 1QP, United Kingdom

MD Biologics

Match pending…
Shared contract value
£8.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 5 awarded suppliers
Award ID
076640-2025-3
Status
active
Location
London, UKM, WC2H 9JQ, United Kingdom

Mercury Pharmaceuticals Limited

Matched by exact name
Shared contract value
£8.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 5 awarded suppliers
Award ID
076640-2025-3
Status
active
Location
London, United Kingdom., UKM, EC2M 1QS, United Kingdom

Sandoz

Match pending…
Shared contract value
£8.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 5 awarded suppliers
Award ID
076640-2025-3
Status
active
Location
Camberley, Surrey, UKM, GU15 3YL, United Kingdom

Teva UK Ltd

Matched by exact name
Shared contract value
£8.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 5 awarded suppliers
Award ID
076640-2025-3
Status
active
Location
Castleford, UKM, WF10 5HX, United Kingdom

Biogen Idec Ltd

Matched by exact name
Shared contract value
£2.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 2 awarded suppliers
Award ID
076640-2025-4
Status
active
Location
Maidenhead, UKM, SL6 3UD, United Kingdom

Teva UK Ltd

Matched by exact name
Shared contract value
£2.7m
Awarded
Not supplied
Contract signed
30 Oct 2025
Suppliers
One of 2 awarded suppliers
Award ID
076640-2025-4
Status
active
Location
Castleford, UKM, WF10 5HX, United Kingdom

Classification

  • CPV33600000 — Pharmaceutical products

Lots

  • Aflibercept (Eylea®)£89.8m
  • Aflibercept Biosimilar£1
  • Ranibizumab vials and Pre-filled Syringes£5.1m
  • Faricimab (Vabysmo®)£51.7m

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
NP33925
Status
complete
Has Recurrence
No
Review Details
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts: An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session. The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Procurement Method
open
Main Procurement Category
goods
Procurement Method Details
Open procedure

Covered By

GPA

Bid Opening

Date
5 Sept 2025, 12:00

Legal basis

Id
32014L0024
Scheme
CELEX

Lot Details

Maximum Lots Bid Per Supplier
9,999,999

Techniques

Has Framework Agreement
Yes

Framework Agreement

Maximum Participants
6

Expected award period

Starts
5 Sept 2025, 12:00

Tender Period

Ends
5 Sept 2025, 12:00

Contract terms

Has Electronic Payment
Yes
Has Electronic Ordering
Yes
Electronic Invoicing Policy
allowed

Classification

Id
33600000
Scheme
CPV
Description
Pharmaceutical products

Submission terms

Languages

en

Bid Validity Period

Duration In Days
90

Submission Method

electronicSubmission

Selection criteria

Criteria

Criterion 1
Type
suitability
Description
Economic operators may be excluded from this competition if they are in breach of any situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015

Applies To

supplier
Criterion 2
Type
technical
Minimum
(a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control. (b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes. (c) Confirmation that artwork for tendered Goods has been provided, where requested in the ITT, to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products. (d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder’s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions. (e) Confirmation that all devices tendered and associated ancillaries which are classed as medical devices will carry the appropriate declaration of conformity for the UK market and display a valid CE, CE UKNI or UKCA mark prior to the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under Technical and Professional ability: Quality Control
Description
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement. (b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent. (c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. (d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond. (e) Potential Framework Participants must be able to demonstrate that all devices tendered and associated ancillaries under this Framework Agreement comply with Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002) and have an appropriate declaration of conformity and display a valid CE, CE UKNI or UKCA mark.

Applies To

supplier

Lots and requirements

Entry 1
Id
1
Title
Aflibercept (Eylea®)
Status
cancelled
Has Options
No
Has Renewal
Yes
Description
Supply of Aflibercept (Eylea®) vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as a single supplier framework to a single Framework Participant.

Value

Amount
89,785,600
Currency
GBP

Renewal

Description
This framework includes the option to extend for any number of periods, up to a maximum overall period of thirty six (36) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Award criteria

Criteria

Criterion 1
Name
Logistics
Type
quality
Description
5
Criterion 2
Type
price
Description
95

Contract period

Duration In Days
360

Submission terms

Variant Policy
notAllowed
Entry 2
Id
2
Title
Aflibercept Biosimilar
Status
cancelled
Has Options
No
Has Renewal
Yes
Description
Supply of Aflibercept Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to five (5) Framework Participants.

Value

Amount
1
Currency
GBP

Renewal

Description
This framework includes the option to extend for any number of periods, up to a maximum overall period of thirty six (36) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Award criteria

Criteria

Criterion 1
Name
Logistcics
Type
quality
Description
5
Criterion 2
Type
price
Description
95

Contract period

Duration In Days
360

Submission terms

Variant Policy
notAllowed
Entry 3
Id
3
Title
Ranibizumab vials and Pre-filled Syringes
Status
cancelled
Has Options
No
Has Renewal
Yes
Description
Supply of Ranibizumab Branded and Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to two (2) Framework Participants.

Value

Amount
5,056,988
Currency
GBP

Renewal

Description
This framework includes the option to extend for any number of periods, up to a maximum overall period of thirty six (36) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Award criteria

Criteria

Criterion 1
Name
Logistics
Type
quality
Description
5
Criterion 2
Type
price
Description
95

Contract period

Duration In Days
360

Submission terms

Variant Policy
notAllowed
Entry 4
Id
4
Title
Faricimab (Vabysmo®)
Status
cancelled
Has Options
No
Has Renewal
Yes
Description
Supply of Faricimab vials and Pre-filled Syringes to NHS Scotland. The Authority has not awarded this Framework to any suppliers.

Value

Amount
51,736,628
Currency
GBP

Renewal

Description
This framework includes the option to extend for any number of periods, up to a maximum overall period of thirty six (36) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Award criteria

Criteria

Criterion 1
Name
Logistics
Type
quality
Description
5
Criterion 2
Type
price
Description
95

Contract period

Duration In Days
360

Submission terms

Variant Policy
notAllowed

Items and delivery

Item 1
Id
1
Related Lot
1

Delivery Location

Description
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

Delivery locations

Entry 1
Region
UKM
Entry 2
Region
UKM

Additional Classifications

Entry 1
Id
33600000
Scheme
CPV
Description
Pharmaceutical products
Item 2
Id
2
Related Lot
2

Delivery Location

Description
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

Delivery locations

Entry 1
Region
UKM
Entry 2
Region
UKM

Additional Classifications

Entry 1
Id
33600000
Scheme
CPV
Description
Pharmaceutical products
Item 3
Id
3
Related Lot
3

Delivery Location

Description
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

Delivery locations

Entry 1
Region
UKM
Entry 2
Region
UKM

Additional Classifications

Entry 1
Id
33600000
Scheme
CPV
Description
Pharmaceutical products
Item 4
Id
4
Related Lot
4

Delivery Location

Description
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

Delivery locations

Entry 1
Region
UKM
Entry 2
Region
UKM

Additional Classifications

Entry 1
Id
33600000
Scheme
CPV
Description
Pharmaceutical products

Buyer, suppliers and contacts

Organisation 1
Id
GB-FTS-115937
Name
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Roles

buyer
centralPurchasingBody

Address

Region
UKM
Locality
Edinburgh
Postal Code
EH12 9EB
Country Name
United Kingdom
Street Address
1 South Gyle Crescent

Details

Classifications

Entry 1
Id
BODY_PUBLIC
Scheme
TED_CA_TYPE
Description
Body governed by public law
Entry 2
Id
07
Scheme
COFOG
Description
Health

Identifier

Legal Name
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Contact

Organisation 2
Id
GB-FTS-324
Name
Sheriff Court House

Roles

reviewBody

Address

Locality
Edinburgh
Postal Code
EH1 1LB
Country Name
United Kingdom
Street Address
27 Chambers Street

Details

Identifier

Legal Name
Sheriff Court House

Contact

Telephone
+44 1312252525
Organisation 3
Id
GB-FTS-50481
Name
Bayer Plc

Roles

supplier

Address

Region
UKM
Locality
Reading
Postal Code
RG2 6AD
Country Name
United Kingdom
Street Address
400 South Oak Way, Green Park

Details

Scale
large

Identifier

Legal Name
Bayer Plc

Contact

Fax Number
+44 1635563693
Telephone
+44 1635563432
Organisation 4
Id
GB-FTS-95762
Name
Mercury Pharmaceuticals Limited

Roles

supplier

Address

Region
UKM
Locality
London, United Kingdom.
Postal Code
EC2M 1QS
Country Name
United Kingdom
Street Address
Dashwood House, , 2nd Floor, 69 Old Broad Street,

Details

Scale
sme

Identifier

Legal Name
Mercury Pharmaceuticals Limited

Contact

Telephone
+44 2085889335
Organisation 5
Id
GB-FTS-141106
Name
Biogen Idec Ltd

Roles

supplier

Address

Region
UKM
Locality
Maidenhead
Postal Code
SL6 3UD
Country Name
United Kingdom
Street Address
Biogen Building 5 Foundation Park, , Roxborough Way, Maidenhead, Berkshire, England,

Details

Scale
large

Identifier

Legal Name
Biogen Idec Ltd

Contact

Telephone
+44 7860270707
Organisation 6
Id
GB-FTS-93451
Name
Teva UK Ltd

Roles

supplier

Address

Region
UKM
Locality
Castleford
Postal Code
WF10 5HX
Country Name
United Kingdom
Street Address
Ridings Point, Whistler Drive, Glasshoughton

Details

Scale
large

Identifier

Legal Name
Teva UK Ltd

Contact

Telephone
+44 07780226334

Additional Contact Points

Entry 1
Telephone
+44 7780226334
Organisation 7
Id
GB-FTS-5312
Name
Celltrion Healthcare United Kingdom Limited

Roles

supplier

Address

Region
UKM
Locality
Slough
Postal Code
SL1 1QP
Country Name
United Kingdom
Street Address
1-7 The Switch

Details

Scale
sme

Identifier

Legal Name
Celltrion Healthcare United Kingdom Limited

Contact

Telephone
+44 7587521510
Organisation 8
Id
GB-FTS-167366
Name
MD Biologics

Roles

supplier

Address

Region
UKM
Locality
London
Postal Code
WC2H 9JQ
Country Name
United Kingdom
Street Address
71-75 Shelton Street, Covent Garden

Details

Scale
sme

Identifier

Legal Name
MD Biologics

Contact

Telephone
+44 7753579782
Organisation 9
Id
GB-FTS-95765
Name
Sandoz

Roles

supplier

Address

Region
UKM
Locality
Camberley, Surrey
Postal Code
GU15 3YL
Country Name
United Kingdom
Street Address
Park View, Riverside Way, Watchmoor Park

Details

Scale
large

Identifier

Legal Name
Sandoz

Contact

Telephone
+44 7766295207

Award information

Award 1
Id
076640-2025-1
Title
Faricimab (Vabysmo®)
Status
unsuccessful
Status Details
unsuccessful

Related lots

4
Award 2
Id
076640-2025-2
Title
Aflibercept (Eylea®)
Status
active

Suppliers

Supplier 1
Id
GB-FTS-50481
Name
Bayer Plc

Related lots

1
Award 3
Id
076640-2025-3
Title
Aflibercept Biosimilar
Status
active

Suppliers

Supplier 1
Id
GB-FTS-95762
Name
Mercury Pharmaceuticals Limited
Supplier 2
Id
GB-FTS-93451
Name
Teva UK Ltd
Supplier 3
Id
GB-FTS-5312
Name
Celltrion Healthcare United Kingdom Limited
Supplier 4
Id
GB-FTS-167366
Name
MD Biologics
Supplier 5
Id
GB-FTS-95765
Name
Sandoz

Related lots

2
Award 4
Id
076640-2025-4
Title
Ranibizumab vials and Pre-filled Syringes
Status
active

Suppliers

Supplier 1
Id
GB-FTS-141106
Name
Biogen Idec Ltd
Supplier 2
Id
GB-FTS-93451
Name
Teva UK Ltd

Related lots

3

Contracts and changes

Entry 1
Id
076640-2025-2
Title
Aflibercept (Eylea®)
Status
active
Award ID
076640-2025-2
Date Signed
30 Oct 2025, 00:00

Value

Amount
9,272,932
Currency
GBP
Entry 2
Id
076640-2025-3
Title
Aflibercept Biosimilar
Status
active
Award ID
076640-2025-3
Date Signed
30 Oct 2025, 00:00

Value

Amount
8,685,992
Currency
GBP
Entry 3
Id
076640-2025-4
Title
Ranibizumab vials and Pre-filled Syringes
Status
active
Award ID
076640-2025-4
Date Signed
30 Oct 2025, 00:00

Value

Amount
2,712,160
Currency
GBP

Recorded locations

  • Buyer location · Edinburgh · UKM · EH12 9EB · United Kingdom
  • Delivery location · UKM

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. ocds-h6vhtk-058262-2025-11-24T16:57:38Zcompiled ·